BALCHEM CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BALCHEM CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $799.02M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $703.64M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $643.71M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $643.68M | Feb 19, 2021 |
| FY2017 | Dec 31, 2017 | $159.26M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $150.72M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $147.08M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $137.73M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $140.76M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $138.51M | Mar 1, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.62M | Feb 20, 2026 |
| FY2025 | Sep 30, 2025 | $267.56M | Feb 20, 2026 |
| FY2025 | Jun 30, 2025 | $255.47M | Feb 20, 2026 |
| FY2025 | Mar 31, 2025 | $250.52M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $240.00M | Feb 20, 2026 |
| FY2025 | Sep 30, 2024 | $239.94M | Feb 20, 2026 |
| FY2025 | Jun 30, 2024 | $234.08M | Feb 20, 2026 |
| FY2025 | Mar 31, 2024 | $239.66M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $228.70M | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | $229.95M | Feb 21, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.90M | Feb 20, 2026 |
| FY2025 | Sep 30, 2025 | $95.45M | Feb 20, 2026 |
| FY2025 | Jun 30, 2025 | $93.11M | Feb 20, 2026 |
| FY2025 | Mar 31, 2025 | $88.17M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $86.34M | Feb 20, 2026 |
| FY2025 | Sep 30, 2024 | $85.36M | Feb 20, 2026 |
| FY2025 | Jun 30, 2024 | $82.99M | Feb 20, 2026 |
| FY2025 | Mar 31, 2024 | $81.51M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $74.99M | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | $76.54M | Feb 21, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.23M | Feb 20, 2026 |
| FY2025 | Sep 30, 2025 | $40.29M | Feb 20, 2026 |
| FY2025 | Jun 30, 2025 | $38.28M | Feb 20, 2026 |
| FY2025 | Mar 31, 2025 | $37.05M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $33.58M | Feb 20, 2026 |
| FY2025 | Sep 30, 2024 | $33.84M | Feb 20, 2026 |
| FY2025 | Jun 30, 2024 | $32.07M | Feb 20, 2026 |
| FY2025 | Mar 31, 2024 | $28.99M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $26.65M | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | $29.08M | Feb 21, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.33M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $182.91M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $159.19M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $145.19M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $127.50M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $111.15M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $102.55M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $107.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $96.90M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $90.84M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.51M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $16.79M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $15.05M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $12.19M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $13.52M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $10.33M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $11.38M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $11.59M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $9.31M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $7.33M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $2.90M | Feb 29, 2016 |
| FY2014 | Dec 31, 2014 | $2.90M | Feb 27, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.56M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $182.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $183.76M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $138.54M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $160.51M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $150.49M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $124.46M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $118.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $110.62M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $107.61M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $49.09M | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $36.14M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $32.08M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $25.79M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $19.17M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $27.53M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $23.03M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $41.30M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $13.20M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $8.19M | Feb 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.60B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.62B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.20B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.17B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.16B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $981.36M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $963.64M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $948.63M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $428.84M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $425.46M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $543.23M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $686.23M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $322.31M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $337.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $412.02M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $289.74M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $346.76M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $427.59M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $938.28M | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $877.02M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $828.23M | Feb 16, 2024 |
| FY2022 | Dec 31, 2019 | $743.67M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $691.62M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $616.88M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $521.03M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $816.38M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $780.03M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $778.91M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $769.51M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $523.95M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $529.46M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $524.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $448.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $441.36M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $439.81M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $997.49M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $897.49M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $814.49M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $732.14M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $656.74M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $590.92M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $528.03M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $464.64M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $388.09M | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.57M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $49.52M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $64.45M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $66.56M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $103.24M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $84.57M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $65.67M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $54.27M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $40.42M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $38.64M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $262.50M | Feb 29, 2016 |
| FY2015 | Dec 31, 2014 | $297.50M | Feb 29, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Feb 27, 2015 |
| FY2012 | Dec 31, 2012 | $0 | Feb 25, 2013 |
| FY2012 | Dec 31, 2011 | $1.41M | Feb 25, 2013 |
| FY2011 | Dec 31, 2010 | $4.91M | Feb 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 21, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 20, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 21, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 21, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 32.06M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 32.53M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 32.25M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 32.15M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 32.29M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 32.37M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 32.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 32.26M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 32.02M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 31.76M | Mar 1, 2018 |